Ascendis Pharma's Weekly CNP Therapy Challenges BioMarin's Daily Voxzogo in Achondroplasia Market
核心洞察
Ascendis Pharma's TransCon CNP awaits FDA approval on November 30 as a weekly treatment for achondroplasia (搜索), competing directly with BioMarin's daily Voxzogo injections.
Phase II data showed TransCon CNP achieved 5.42 cm per year growth velocity versus 4.35 cm for placebo, while Voxzogo demonstrated 1.57 cm improvement over placebo in Phase III trials.
The global achondroplasia (搜索) market represents over $5 billion opportunity with 24,000 eligible patients, though Voxzogo currently captures only 17% market penetration.
The FDA is set to decide on November 30 whether to approve Ascendis Pharma's TransCon CNP, a weekly treatment for achondroplasia (搜索) that could significantly challenge BioMarin's market-leading Voxzogo. The decision comes nearly four years after Voxzogo became the first approved therapy for the rare genetic disorder that affects bone growth in children.
When Ascendis Pharma announced TransCon CNP results, BioMarin's stock fell 17%, reflecting investor concerns about potential competition. Despite the limitations of cross-trial comparisons, TransCon CNP's profile appears competitive in terms of efficacy, safety and convenience, with its once-weekly dosing schedule representing a strong differentiator compared to Voxzogo's daily subcutaneous injections.
Market Opportunity and Current Penetration
The achondroplasia (搜索) treatment market presents substantial opportunity, with approximately 24,000 clinically eligible patients from birth to 18 years of age globally. Voxzogo has achieved around 17% market penetration, treating approximately 4,000 patients. This implies a global market opportunity of just north of $5 billion assuming full penetration.
Achondroplasia (搜索) affects one in 15,000 to one in 40,000 newborns and represents the most common cause of dwarfism (搜索). The condition is caused by a gain-of-function mutation in the FGFR3 (搜索) gene, leading to over-activation of the FGFR3 receptor and suppression of bone development cells, effectively stalling bone growth at the growth plate.
Competing CNP-Based Approaches
Both Voxzogo and TransCon CNP work by mimicking C-type natriuretic peptide (CNP), a naturally occurring hormone that counteracts FGFR3 (搜索) activity to promote bone growth. BioMarin's Phase III data showed Voxzogo improved annual growth velocity by 1.57 cm per year at 52 weeks compared with placebo, supported by more than 6,000 patient-years of data across clinical development and real-world use.
In contrast, Ascendis' Phase II ACcomplisH study demonstrated TransCon CNP achieved an annualized growth velocity of 5.42 cm per year versus 4.35 cm per year in placebo comparators. The difference was statistically significant in favor of TransCon CNP, according to a November 2023 publication in The Lancet, which also demonstrated a favorable overall safety profile.
BioMarin maintains certain competitive advantages, including a commercial footprint spanning around 50 countries and a stronger label that includes approval for infants. "The majority of children in the United States are actually diagnosed prenatally and often, the decision to treat is made prenatally," noted industry analyst Sadaf Javed. "BioMarin is the only one that is indicated in infants."
Current consensus guidelines published in Nature Reviews Endocrinology emphasize that "treatment should be initiated as early as possible," pointing to new data suggesting that starting intervention within the first months of life could lead to better growth improvements.
Alternative Mechanisms Target Root Cause
Beyond CNP-based therapies, several companies are pursuing approaches that target the underlying genetic cause of achondroplasia (搜索). BridgeBio is developing infigratinib, a small-molecule drug that blocks the mutant FGFR3 (搜索) receptor, hitting achondroplasia "directly at its genetic source."
In November 2023, BridgeBio published Phase II PROPEL 2 study data showing a 2.5 cm per year increase in annualized growth velocity at 18 months of follow-up. Notably, infigratinib also demonstrated significant improvement in body proportionality, defined as the ratio between patients' upper and lower body segments—an effect not observed with Voxzogo and TransCon CNP.
"We have heard from both families of children with achondroplasia (搜索) and clinicians that there is a significant need for an oral treatment option," said Justin To, CEO of Skeletal Dysplasias at BridgeBio. If approved, infigratinib would be the first oral treatment option for children with achondroplasia.
BridgeBio is currently running the fully-enrolled Phase III PROPEL 3 study, with topline data expected early next year. Tyra Biosciences is also developing TYRA-300 (dabogratinib (搜索)), positioned as a more selective FGFR3 (搜索) inhibitor than infigratinib, currently in mid-stage studies for achondroplasia (搜索).
Pipeline Developments and Future Competition
BioMarin isn't standing still in the face of competition. The company is developing BMN-333, a long-acting CNP formulation designed to sustain elevated CNP levels and improve upon Voxzogo's once-daily dosing regimen. BioMarin plans to start a pivotal Phase II/III study for BMN-333 in the first half of 2026.
The company is also expanding Voxzogo's applications beyond achondroplasia (搜索), with a late-stage program for hypochondroplasia (搜索) and Phase II studies for Noonan syndrome (搜索) and Turner syndrome (搜索).
CNP-based therapies face certain limitations, including vasodilation concerns that can lead to low blood pressure, and the practical burden of frequent injections due to the peptide hormone's relatively short half-life. These challenges keep the field open for alternative approaches that could potentially offer superior efficacy compared to existing CNP analogs.
"It's the everyday milestones that families share that drive us," said BioMarin's Chief Commercial Officer Cristin Hubbard. "Reaching a car door, riding a roller coaster, turning on a light switch, putting up his or her own hair. These moments, and the clear unmet need, are why we remain deeply committed to leading innovation in rare conditions."